Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
PARIS:MEDCL
Holding FR:MEDCL?
Track your performance easily
MEDCL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.67 - €19.00
Previous Close€15.3
Volume41.65K
Average Volume (3M)61.10K
Market Cap
€447.26M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Dec 03, 2024EPS Estimate
-€0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares OutstandingN/A
10 Day Avg. Volume43,382
30 Day Avg. Volume61,100
Standard Deviation0.18
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)26.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.43Price Target Upside32.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial MilestonesMedincell may receive up to $117M in development and commercial milestones for mdc-TJK and up to $105M in commercial milestones for UZEDY, plus royalties on all net sales of both products.
Market SentimentReal-world analyses on UZEDY underscore the positive market sentiment and robust uptake, with expectations for accelerated market penetration.
Product DevelopmentThe jointly developed MedinCell / Teva product candidate could be the first long-acting olanzapine with a favorable safety profile, since other LAIs of olanzapine have been associated with a black box warning on their FDA-authorized labels for post-injection delirium/sedation syndrome (PDSS), which severely limits their use.
Bears Say
Commercial RisksCommercial risks are present, especially regarding the ongoing promotion of UZEDY and the future launch of mdc-TJK.
Partnership RisksThere are concerns about potential partnership risks, particularly in terms of relationships with Teva and AbbVie.
Regulatory ApprovalThere is a risk of not being able to submit a regulatory application for approval of mdc-TJK in the U.S. in a timely manner.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
― Other Institutional Investors
99.91% Public Companies and
Individual Investors
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €5.67 and its highest was €19.00 in the past 12 months.
What is MedinCell SA’s market cap?
Currently, no data Available
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 03, 2024 which is in 23 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 10, 2024. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.17.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -€0.19.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 29,103,380 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.587%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
---
MedinCell SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
MEDCL Stock 12 Month Forecast
Average Price Target
€21.43
▲(32.45% Upside)
Technical Analysis
Best Analysts Covering MEDCL
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+65.20%
reiterated a buy rating 2 months ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +65.20% per trade.
---